📽 Excitement never wanes when it comes to innovations from Insilico. Last year, we proudly announced our new #PCC Inhalation Solution for Idiopathic Pulmonary Fibrosis (#IPF). This breakthrough formulation promises to be a safer and more effective treatment option. By allowing patients to directly inhale the medication, the drug molecule can reach the lungs more efficiently, bypassing other organs. For a lung disease like IPF, this #targeteddelivery method just makes sense. This is the same molecule that is undergoing Phase II studies in both the US and China. Recently, we received positive results from the Phase IIa readout. Stay tuned.
Insilico Medicine
Biotechnology Research
Boston, Massachusetts 58,295 followers
#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity
About us
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
- Website
-
http://www.Insilico.com
External link for Insilico Medicine
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2014
- Specialties
- artificial intelligence, deep learning, reinforcement learning, drug discovery, aging research, longevity, biomarker development, Generative adversarial networks, GANs, and GANs-RL
Locations
-
Primary
1000 Massachusetts Ave
Boston, Massachusetts 02138, US
-
345 Park Ave S
New York, NY 10010, US
-
1 Science Park East Avenue, Hong Kong Science Park, Pak Shek Kok
Unit 307A, Core Building 1
New Territories, HK
Employees at Insilico Medicine
Updates
-
Another busy week of conferences ✈ Taking place today at the University of Toronto, and part of the Acceleration Consortium is the AC Seminar Series: From Algorithm to Human Clinical trials led by Alex Zhavoronkov, PhD (https://lnkd.in/ek-yDWaY). Next up will be a Panel Discussion led by Petrina Kamya, Ph.D. "Revolutionizing Healthcare with Responsible #GenerativeAI", part of IQPC's 2nd Annual Generative AI Week in Alpharetta, Georgia. Join this panel discussion to delve into how pioneers in Generative AI for #healthcare are approaching, predicting & overcoming challenges in this space. (https://lnkd.in/eEYuGgT3) We hope to catch you at an upcoming event! To catch up on everything at Insilico Medicine, or to book a demo with our team, please visit: https://insilico.com/ #AIconferences #GenerativeAI #Healthcareevents
-
Insilico Medicine reposted this
Reimagining Healthcare | Physician Executive - Pharma & Biotech | Global Health, Longevity & Pharmaceutical Medicine | MBA | Strategy & Business Dev. | Innovation & Entrepreneurship | Venture Creator, Builder & Investor
𝐀 𝐍𝐞𝐰 𝐀𝐯𝐞𝐧𝐮𝐞 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 At Insilico Medicine, we are at the forefront of harnessing AI to unlock groundbreaking therapeutic targets, and one of the most promising avenues we’re exploring is MAT2A—an enzyme central to cellular metabolism and gene regulation with immense potential in oncology and beyond. Our AI drug discovery platform has identified MAT2A as a prime target for cancers with MTAP deficiency—a genetic alteration found in approximately 15% of cancers, including glioblastoma and pancreatic cancer. What is MAT2A? - MAT2A regulates the synthesis of S-adenosylmethionine (SAM), a pivotal molecule that regulates key biological functions such as: 1- Gene Expression: SAM facilitates methylation, influencing the activation and silencing of genes. 2- Protein Modification: It is integral to post-translational modifications that can alter protein activity and stability. 3- Metabolism: MAT2A helps maintain cellular metabolic pathways, which are often dysregulated in cancer. Highlights: • MAT2A sustains the survival of MTAP-deficient tumors, a genetic aberration present in ∼15% of all cancers. • Multiple new MAT2A inhibitors have reached the clinical testing stage as both a monotherapy or in combination. • Understanding which cancer subtypes may benefit from MAT2A PRMT5 inhibition is critical to advancing MAT2A inhibitors in the clinic. • Recent Phase 1 and 2 findings improve our understanding of the potential safety limitations of these inhibitors, particularly as a new generation of inhibitors is being developed. At Insilico Medicine, our technology has been at the cutting-edge of biology and chemistry, paving the way for the next generation of cancer treatments and beyond. Please check out our paper on MAT2A inhibition that just got published. Our MAT2A inhibitor has IND clearance and potential for combo with PRMT5 inhibitors. Stay tuned as we continue to push the boundaries of what’s possible in healthcare innovation. #AIDrugDiscovery #MAT2A #PrecisionMedicine #Oncology #AgeRelatedTherapies #InsilicoMedicine
-
🇸🇪 Join ♠️ Aisyah S. from Insilico Medicine, at the AI x #Longevity Summit 2024 on October 23rd, organized by Epicenter Stockholm, AI Cockpit, and the Swedish Longevity Cluster. This Summit combines the perspectives of Epicenter's AI Cockpit and Swedish Longevity Cluster, to illustrate how AI can be a tool to realise the aim of extending our healthy lives. #longevity #healthyliving #AIhealthcare
SPEAKER DROP #2 for the AI x Longevity Summit 2024: Aisyah S. (Insilico Medicine)! Aisyah Sjöholm, MD, is a Senior Business Development Manager at Insilico Medicine, an AI-driven pharma-technology leader committed to extending healthy, productive longevity by transforming drug discovery and development through generative AI. Learn more about Insilico Medicine here: https://www.insilico.com/ On the 23rd of October, Aisyah will enter the stage to share her expertise. Get your ticket down below, and stay tuned here on Linkedin for our upcoming speaker drops. 🧬 About the AI x Longevity Summit: This summit combines the perspectives of Epicenter's AI Cockpit and Swedish Longevity Cluster, to illustrate how AI can be a tool to realise the aim of extending our healthy lives. Organized by Epicenter Stockholm, AI Cockpit and Swedish Longevity Cluster. 📆 OCT 23 📍 Epicenter Stockholm 👉 Sign up here: https://lnkd.in/dH3iePaM 🧬 Memberships & Discounts. - Epicenter Member? You have an offer to unlock, connect with Matilda Muhr Göransson for your code. - Member of Swedish Longevity Cluster or AI Cockpit? You have an offer to unlock, connect with Per Söderström, Linus Petersson or Ingrid af Sandeberg for your code. See you at Epicenter Stockholm. #AI #Longevity #Summit #Epicenter
-
Big pharma, biotech relations ‘won't necessarily be symbiotic’ in future AI landscape: S&P The latest from Fierce Biotech is now available: https://lnkd.in/d9-NJgx4
-
Thank you to Petrina Kamya, Ph.D., Global Head of AI Platforms, Insilico Medicine and Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation for leading the Fundamentals of #GenerativeAI at Discovery on Target 2024! Thank you to all of the attendees and organizers. #BostonDOT24 Cambridge Healthtech Institute #BostonBiotech #DrugDiscovery
-
Insilico Medicine reposted this
The rarely-spoken dilemma in the AI-powered drug discovery industry is the conflict between traditional drug development expertise and AI software developers. AI specialists emphasize quantity and data, while traditional drug hunters are often skeptical of the "black box" nature of AI. People are always drawn to the latest updates in technology but often overlook the critical importance of solid interdisciplinary collaboration. The true potential of AI can only be realized when it is aligned with a specific area of expertise, making it genuinely useful to human society. At Insilico Medicine, we have fostered a "patient-first" culture to bridge this gap. Our AI experts and drug developers work together, united by a common goal: to bring hope to patients in need. By encouraging this collaborative approach, we ensure that our AI capabilities are directed towards meaningful and impactful outcomes in healthcare. #AI #DrugDiscovery #Collaboration #Innovation #Healthcare #Technology #Interdisciplinary #PatientFirst #InsilicoMedicine #MedicalResearch #Pharma #Biotech
-
🎧 Listen in to the latest from Vibe Bio! Alex Zhavoronkov joins Ray Dogum on the #VibeCast to discuss #AI and robotics in the #biopharma and #life sciences space. Listen here to catch up on all things drug discovery, deep learning, and #longevity. Full transcript and video available: https://lnkd.in/e9ytGj5f
Have humans reached an inflection point in our artificial intelligence journey? 🤖 For decades, AI market cycles have come and gone, reflecting our quest for more efficient thinking machines to partner with. Similarly, the pursuit of extending human lives has been a huge interest since antiquity. In a recent #VibeCast by Vibe Bio interview with Alex Zhavoronkov, co-founder and CEO of Insilico Medicine, we explored some of the mind-bending opportunities that AI and robotics have to offer in biopharma and life sciences. As a veteran aging and longevity researcher, Alex has been at the forefront of increasing healthspan, identifying novel drug targets, and deep learning models. Since 2012, he has published over 200 peer-reviewed research papers with over 30 papers in the field of generative adversarial networks, generative reinforcement learning, and multi-modal transformers, and 3 books, including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”. So if you think we are approaching the AI inflection point (singularity?!) and want to learn how it impacts human lifespan, then I highly recommend checking out episode 52 today on your favorite player. We'd love your feedback and comments! Full transcript and video available: https://lnkd.in/e9ytGj5f Super grateful for the Frontiers Health team and Nana Bit-Avragim (she/her) for their partnership and connecting me with Alex! Both Alex and Nana will be speaking at the Frontiers Health event in Berlin, Oct. 17-18, 2024. #artificialintelligence #ai #biotech #longevity #aging #drugdevelopment
The Future of Aging, AI, and Robotics with CEO of Insilico Medicine - Alex Zhavoronkov, PhD | VibeCast Episode 52
https://vibebio.com
-
📅 Be sure to register for the first #ACSeminar! Acceleration Consortium From Algorithm to Human Clinical Trials: End-to-End Drug Discovery and Development Using #GenerativeAI and Robotics Monday October 7, 2:30 PM – 3:30 PM EST (in person at University of Toronto or online) Learn more register: https://lnkd.in/g-65y3t5 #Toronto #DrugDiscovery
Register today for the first AC seminar of the fall season featuring Alex Zhavoronkov founder and CEO of Insilico Medicine! 💊💡 Explore AI's transformative role in drug discovery and development, featuring case studies, industry insights, and discussions on generative AI's applications in multi-species life models and aging research. From Algorithm to Human Clinical Trials: End-to-End Drug Discovery and Development Using Generative AI and Robotics Monday October 7, 2:30 PM – 3:30 PM EST (in person at University of Toronto or online) Learn more register: https://lnkd.in/g-65y3t5 #Seminar #AILecture #DrugDiscovery #GenerativeAI #Robotics
-
🌎 Thank you to Lisbeth Kaufman and to everyone at Amazon Web Services (AWS) NY #ClimateWeek 2024. 🌍
🌎 NY Climate Week 🌎 is a good time to reflect on what’s at stake and why we are all working in climate tech. Simply put, we need a second industrial revolution to transition to a net-zero global economy ASAP. We need to do it in just 26 years, one-tenth of the time of the first industrial revolution. That is a staggering timeline. But there are so many reasons to be optimistic. We explored these reasons at the sold out AWS CLIMATE TECH & AI FORUM during NY Climate Week. Unlike during the first industrial revolution we have incredible technology that can help accelerate the fight against the climate crisis. At the AWS CLIMATE TECH & AI FORUM during NY Climate Week we dove into one set of technologies - Artificial Intelligence- and how some of the most innovative Climate tech startups are using it to more quickly build climate solutions. I found it inspiring to hear from Lukky A., Alex Zhavoronkov, Allison Wolff, Sam Ramadori, Kelly Zheng, and Josh Couchman about how they are building with AI on AWS. They shared how Insilico Medicine has built a GenAI platform with foundational models that invent new sustainable materials, BrainBox AI reduces buildings’ carbon footprint, Connect Earth uses AI to help people make more climate-friendly purchases, Climate X uses AI and Trillions of datapoints to track and respond to climate risk, Vibrant Planet is building a generative ai foundational model to prevent wildfires, and Coastal Carbon is building generative ai foundational models to monitor the world’s natural ecosystems. It was also an honor to hear from Helena Fu the Chief AI Officer of the U.S. Department of Energy (DOE) on how they are supporting startups and advancing AI. Clay Dumas, Rajesh Swaminathan, and Daniel Gross shared wisdom about how they see the role of AI in climate tech. All in all, there are so many problems to address. But there are so many brilliant people with clear visions, using advanced AI tools to more quickly develop solutions. After NY Climate Week I feel more confident that we can figure this thing out and do it in time to curb the worst impacts of the climate crisis. Thank you Stephen Blalock, Deepam Mishra, Benoît de Chateauvieux, David Roberts, Nate Repensky, Kartikeya Sharma, Brooke Mullen, Abby Chittams, Meaghan Casey, Chris Tuck, Peter Whitney, Kommy Weldemariam for all of your help making this a great event. #nycw #nyclimateweek, #climatetech #climatecrisis, #startups #venturecapital #generativeai #ai #genai #artificialintelligence #aws #cloudcomputing #sustainability
-
6